Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Executives Outline Expansion Plans at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

Global expansions highlighted
This year’s DCAT Member Company Announcement Forum, which was held on March 21, 2022, kicked off DCAT Week 2022 with CEOs and senior executives highlighting major news announcements from their companies with developments across the global bio/pharmaceutical manufacturing value chain. DCAT Week, held March 21–24, 2022, is the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing.

Expansions in biomanufacturing (drug substance), both traditional biologics and new modalities, such as cell and gene therapies, including select investments in mRNA manufacturing, were a major area of focus of several companies’ announcements, with certain companies highlighting billion-dollar plus expansion plans.

So which companies are making the news in biomanufacturing? On the CDMO side, Thermo Fisher Scientific, Samsung Biologics, Lonza, Catalent, AGC Biologics, and IDT Biologika are moving forward with key expansions in biologics, as is Cytiva, the former Biopharma business of GE Life Sciences, now part of Danaher Corporation, and a large supplier of products supporting bioprocessing.

Several of these CDMOs with integrated capabilities in biologic drug substance and drug-product manufacturing also provided updates on their expansions in fill–finish/sterile drug-product development and manufacturing (Thermo Fisher Scientific, Lonza, Catalent, and IDT Biologika) as did Selkirk Pharma, a CDMO of injectable products.

Also on the drug-product side, Catalent highlighted the integration of its $1-billion acquisition of Bettera, providing it with innovative dose technologies for consumer healthcare products.  CordenPharma outlined the acquisition of three drug-product manufacturing facilities to expand its capacity for oral dosage forms and other dosage forms (sachets, non-sterile liquids).

On the small-molecule drug substance side, several companies announced expansions. WuXi STA is proceeding with a major expansion plan in its global R&D and manufacturing network for small-molecule APIs, including high-potency APIs, as well as for oligonucleotides, peptides, and their conjugates in addition to investments in flow chemistry and biocatalysis. HAS Healthcare Advanced Healthcare Systems (formerly Helsinn Advanced Synthesis) is progressing a multi-year expansion plan, and Cambrex announced a $100-million expansion in small-molecule API development and manufacturing.

Details of all these announcements, including investment amounts, capacity additions, and timelines for completion/start-up are outlined in the new stories below.  Plus, other DCAT Member Companies are making the news: watch for the upcoming April 8th issue of DCAT Value Chain Insights for highlights.

Recent Feature Articles

Bio/Pharma’s Rising Stars: The Companies Emerging on the Industry’s Radar

By
Which bio/pharma companies and CEOs may be under the industry’s radar but are executing better-than expected performance and winning strategies for their companies? What products—development and commercial—are delivering? DCAT Value Chain Insights takes an inside look.

A Shortage of Inspectors Curtailing FDA Inspections: The Impact on Pharma

By
FDA conducted 621 foreign and 444 domestic inspections in fiscal year 2023, which was up from pandemic levels when in-person inspections were paused, but 36% fewer than pre-pandemic levels. A shortage of inspectors is a major factor. What’s the impact on Pharma?

A Look Ahead: Bio/Pharma’s Top Policy Issues in US Elections Aftermath

By
Following the US Presidential election this week, two industry groups, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), issued statements broadly highlighting key policy issues of interest. What’s on the agenda?

A Strong Contract ADC Market Drives Expansions in High-Potency Manufacturing

By
Driven by strong demand in the oncology drug market, high-potency manufacturing continues to be an active area of investment for CDMOs/CMOs for both drug substances and drug products. Growth in the contract market for antibody drug conjugates, one component, is projected in the double-digits.